Citations

Clear

2358 citation(s) found for "Yu, Long".

A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk
Eriksson, Mikael , Czene, K, Scott, C, Stoddard, Shawn, Smith, Hugh, Hall, Per , Vachon, C, Scott, Christopher G. , Vachon, Celine M. , Czene, Kamila , Czene, Kamila , Scott, Christopher , Vachon, Celine M. , Hall, Per N , Eriksson, Mikael , Stoddard, Shawn M.

Mayo Clinic

Science Translational Medicine | May 20, 2026 | Volume: 18 | Issue: 850 | Pages: No page available

10.1126/scitranslmed.ady7414 | PMID 42160452 Get It

Image-derived artificial intelligence (AI) risk models have shown promise in short-term risk assessment for improving breast cancer (BC) screening. No image-derived long-term AI risk model for primary prevention has been developed and externally validated. Individuals aged 31 to 94 years were recruited between 2010 and 2020 in two population-based case cohorts (Olmsted County, Minnesota, US, and KARMA, Sweden) and one hospital-based case-control study (EMBED, Atlanta, US). Median follow-up in the case cohorts was 10 years, with BCs diagnosed through June 2022. Additional validation was performed in EMBED with 3-year follow-up. An AI risk model was developed in Sweden, and we report independent validation in Olmsted/KARMA/EMBED. Absolute 10-year risks were estimated at study entry. Time-dependent discriminatory performance [AUC( t )] and expected-to-observed events (E/O) were estimated. Comparisons were performed with clinical risk tools and the image-based Mirai tool. Across Olmsted/KARMA, 8696 individuals (mean age, 54.4±10.6) and 1633 individuals with incident BC (mean age, 57.0±10.6) were included. Average 10-year risks were 3.83 and 3.14%, and E/O ratios were 0.99 and 0.99. Ten-year AUC( t ) for invasive BCs were 0.72 in Olmsted and 0.72 in KARMA. Similar discriminatory results were observed in EMBED. Our AI risk tool performed significantly better than Mirai in Olmsted/KARMA/EMBED. In KARMA, in the top 10% of high-risk individuals, the AI risk tool predicted 33% of BCs compared with 23%/20%/24% predicted by Tyrer-Cuzick-v8/BCSC-v3/Mirai (all P < 0.01). The 10-year image-derived AI risk model showed significantly higher performance than clinical risk models and Mirai in diverse populations, supporting its clinical potential for primary prevention.
Custom Implants for Complex Acetabular Defects Provide Excellent Mid- to Long-Term Survivorship
Sierra, Rafael J. , Sierra, Rafael J

Mayo Clinic

Journal of Bone and Joint Surgery | May 20, 2026 | Volume: 108 | Issue: 10 | Pages: 683-684

10.2106/jbjs.25.01538 | PMID 42159562 Get It

Long-Term Survey to Assess Recurrence and Complications of Surgically Treated Pleomorphic Adenoma
Rourk, Katelyn S. , Hidalgo, C. , Shurtz, Anne K., Tasche, Kendall K. , Price, Daniel L., Abel, Kathryn M. Van , Moore, Eric J., Hidalgo, Cecelia M, Van Abel, Kathryn M , Yin, Linda X , Rourk, Katelyn , Price, Daniel L. , Yin, Linda X. , Moore, Eric J.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00034894261453714 | PMID 42152554 Get It

Objective(s): To (1) report on the long-term recurrence rate of surgically managed pleomorphic adenoma (PA) and (2) assess long-term surgical outcomes after parotidectomy Methods: Cross-sectional survey of all patients with a pathologic diagnosis of PA who underwent surgical management in a tertiary care center from 01/1997 to 12/2023 and had access to an electronic patient portal. Surveys were delivered via electronic patient portal or phone call with 6 questions to assess recurrence and long-term surgical outcomes. Time to first recurrence and recurrence free survival were analyzed using a Kaplan-Meier curve. Results: Seven hundred-forty-five patients met inclusion criteria and received the survey, with a 56% response rate (n = 420). The clinical median follow-up length was 51 days, which extended to a median length of 6.2 years following the survey. The median change in follow-up length was 5.37 years ( P < .001). The recurrence rate was 1% at 5 years, with a median time to first recurrence of 7.54 years. 13% and 9% of responders reported facial asymmetry and incisional cosmetic concerns, respectively. 33% of patients reported experiencing Frey syndrome, which increased from 5.2% of survey responders with documented Frey syndrome at their original post-operative assessment. Conclusion: Long-term assessment of PA outcomes confirms low recurrence rates, suggesting regular surveillance of recurrence is likely unnecessary. Complaints of Frey syndrome increased in frequency with longer term follow-up, which should be considered during patient counseling. Level of Evidence: 3
A96-02 Isoflurane or Propofol for Sedation of Mechanically Ventilated Adults in the ICU: Results of the Inspire ICU Trials
Beitler, J R, Boncyk, C, O'Gara, B P, Englert, J A, Sachdev, A, Owens, R L, Baram, M, Chang, S Y, Berra, L, Blank, R D, Kim, C, Tanios, M A, Fort, A, Lubinsky, G, Odish, M F, Eisinger, G J, Santarisi, A, Serra, A L, Leon, J Espinosa, Garcia, I, Arboleda, A de Lima, Olney, S J, Dzierba, A L, Capers, K, Patel, M, Park, P K, Rengel, K, Carr, J R, Hill, N S, Brainard, J, Hudock, K M, Faisal, H, McDonagh, D, Smischney, N J, Mireles-Cabodevila, E, Nates, J L, Knox, D, Faugno, A J, Fuchita, M, Hite, R, Rizk, E, Jabaley, C, Peltan, I D, Yong, C M, Sheppard, K, Pun, B, Sverud, I, Sackey, P, Hughes, C, Investigators, INSPIRE ICU, Jabaley, Craig S. , Jabaley, Craig S , Beitler, Jeremy R. , Boncyk, Christina S. , O’Gara, Brian , Englert, Joshua A. , Sachdev, Alisha , Owens, R.L., Berra, Lorenzo M. , Tanios, Maged A. , Odish, Mazen Faris , Eisinger, Gregory J. , Santarisi, Abeer , Olney, Sara, Dzierba, Amy L. , Park, P.K., Rengel, Kimberly F. , Hill, N S, Hudock, Kristin , Smischney, Nathan J. , Mireles‐Cabodevila, Eduardo , Nates, Joseph L. , Faugno, Anthony J. , Sverud, Ida, Sackey, Peter , Hughes, Christopher G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4657 Get It

Abstract Introduction Sedation is routinely administered to facilitate comfort and tolerance of life support for critically ill adults dependent on invasive mechanical ventilation. Isoflurane, a widely used anesthetic during surgery, has properties that may also benefit ICU patients requiring continuous sedation. However, efficacy as a sedative and safety in this population is not well established. Methods We conducted two identically designed multicenter randomized trials, INSPIRE ICU1 and INSPIRE ICU2, at hospitals across the US. Ventilator-dependent adults were randomly assigned in a 1.5:1 ratio to receive either inhaled isoflurane or intravenous propofol as the first-line sedative for up to 48 ± 6 hours, targeting a sedation depth between Richmond agitation-sedation scale (RASS) -1 (drowsy) to -4 (responsive only to physical stimuli). Isoflurane was administered via an anesthetic conserving device (Sedaconda ACD-S). In both arms, opioids were permitted at the lowest dose required to achieve freedom from pain. The primary outcome was the percentage of time at target sedation level, assessed as a noninferiority outcome with pre-specified margin of 15%. Secondary outcomes included opioid exposure, wake-up time after end of treatment, time to extubation, and proportion of time with spontaneous breathing effort. Results A total of 470 combined participants were included in the two trials. In each trial, 142 patients were randomly assigned to isoflurane and 93 to propofol. In INSPIRE ICU1, percentage of time within target sedation depth was 77.1 [53.2, 89.9] % with isoflurane and 80.9 [58.2, 96.4] % with propofol (difference -1.5 [-8.9, &gt;99] %; p &lt; 0.01 for noninferiority). In INSPIRE ICU2, percentage of time within target sedation depth was 72.6 [66.4, 78.9] % with isoflurane and 74.5 [67.5, 81.5] % with propofol (difference -1.9 [-9.4, &gt;99] %; p &lt; 0.01 for noninferiority). In both trials, patients assigned to isoflurane received significantly less opioid, measured as fentanyl equivalents, during the treatment period. In INSPIRE ICU2, participants receiving isoflurane were significantly likelier to exhibit spontaneous breathing efforts, but this finding was not replicated in INSPIRE ICU1. There were no significant differences in time to wake-up or time to extubation between groups in either trial. No episodes of malignant hyperthermia or propofol infusion syndrome were reported. Adverse events were comparable in type and frequency between groups. Conclusions In two US multicenter trials, isoflurane was noninferior to propofol for maintaining target sedation depth in adults undergoing invasive ventilation, and was associated with significantly lower opioid exposure. (NCT05327296, NCT05312385) This abstract is funded by: Sedana Medical
D25-23 The Effects of a High Fermented Food Diet on Long Covid Neuropsychiatric Symptoms; A Pilot, Single-blinded, Randomized Controlled Trial
Harris, B, Jahanian, S, Ahmed, A S, Mahmoud, M, Zaki, A A, Hurt, R T, Ganesh, R, Karnatovskaia, L, Ganesh, Ravindra , Karnatovskaia, Lioudmila V.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1100 Get It

Abstract Rationale Long COVID (LC) has affected approximately 400 million people worldwide, with about 20 million in the US. LC is characterized by a host of new symptoms, including neuropsychiatric disorders including cognitive impairment. Disruption of the gut microbiome has been correlated with symptoms of LC. This study examined whether gut microbiome modulation via intake of probiotic fermented foods mitigated psychiatric and cognitive impairments. Methods This was a pilot trial performed at a single academic medical center that enrolled and randomized patients with LC 1:1 into the treatment vs. control arm. Those enrolled into the treatment arm received teaching on the gut microbiome, its relationship to LC, and were encouraged to eat a diet high in probiotic fermented foods for 12 weeks. Those in the control arm did not receive the teaching and were encouraged to eat their normal diet. Diets were tracked using the Mayo Clinic Diet application on a smart phone at least three days per week, and those in the treatment arm received routine calls to discuss protocol adherence and gather subjective feedback on the trial. Neuropsychiatric questionnaires (HADS, IES-R, EQ-5D-5L, and MoCA Blind) were completed at enrollment and upon completion of the trial. Questionnaire scores were evaluated for changes using a paired t-test, with statistical significance defined as a p-value &lt;0.05. Correlation between the fermented food intake and improvements in questionnaires was completed using the Spearman test. Results 43 patients were enrolled; 18 patients in the treatment arm and 20 patients in the control arm completed the trial. Groups did not differ by age, race, education, or baseline neuropsychiatric testing. There was a significant increase in fermented food intake in the treatment arm over the duration of the study. Those in the treatment arm had improvements in questionnaires related to anxiety, PTSD, and quality of life. Those in the control arm only had improvements in reported overall quality of life. Intra-group changes can be seen in Table 1. Correlations between fermented food intake and change in questionnaire scoring showed numerical but not statistically significant improvements in many of the questionnaires, except for the MOCA questionnaire and EQ-5D-5L Self-Care question. Conclusion Implementing a diet high in fermented foods in patients with LC appears to have some signal for improvement in neuropsychiatric symptoms. Completing a larger trial would help clarify if changes would be statistically significant. This abstract is funded by: Mayo Clinic Critical Care Research Committee
Six-Month Outcomes in Children With COVID-19 or Multisystem Inflammatory Syndrome in Children
Howard, Leigh M. , Calvert, Alexis, Stopczynski, Tess , Klintworth, Steven R., Soslow, Jonathan H., Spieker, A, Hilmes, Melissa A. , Dalal, Aarti S., Ruth, Natasha, Mahle, William T. , Schneider, James, Michaels, Marian G., Acker, Karen P. , Danziger-Isakov, Lara, Gans, H, Orr, William B. , Choueiter, Nadine , Kantor, Paul F., Chandani, Harsha K., Chakraborty, Rana, Narula, Pramod, Rossano, Joseph, Singh, Rakesh K. , Trachtman, Rebecca, Pascual, Virginia , Martinez, Olivia M. , Diamond, Betty, Sanz, Ignacio, Boss, Jeremy M., Goldmuntz, E, Morrison, Yvonne, Welch, Beverly, Halasa, Natasha , Webber, Steven A. , Diamond, Betty , Dalal, Aarti , Wilkinson, James D. , Soslow, Jonathan H. , Spieker, Andrew J. , Moore, Paul E. , Ruth, Natasha M. , Michaels, Marian G , Danziger‐Isakov, Lara , Kelly, Matthew S. , Kantor, Paul Fraser , Chandnani, Harsha K., Chakraborty, Rana , Rossano, Joseph, Arditi, Moshe , Trachtman, Rebecca A. , Krams, Sheri M. , Sanz, Igñacio , Boss, Jeremy M. , Bridges, Nancy D. , Goldmuntz, Ellen

Mayo Clinic

Hospital Pediatrics | May 14, 2026 | Volume: 16 | Issue: 6 | Pages: 525-535

10.1542/hpeds.2025-008765 | PMID 42128419 Get It

OBJECTIVES We aimed to characterize the frequency of major complications of acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C) and adolescents present at 6 months after initial presentation. METHODS The Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM) study was a prospective cohort at 20 US pediatric academic medical centers. Individuals aged younger than 21 years meeting any of the following were enrolled: SARS-CoV-2 detection within 7 days, Centers for Disease Control and Prevention (CDC) MIS-C criteria, or CDC MIS-C criteria except having involvement of 1 organ system. The study was designed to assess the proportion of children with major complications (cardiovascular, pulmonary, gastrointestinal/hepatic, renal, and/or neurologic) 6 months after presentation. RESULTS Data were analyzed on 229 hospitalized participants: 59 with COVID-19 (mean age 10.4 years; SD, 5.5) and 170 with MIS-C (mean age 10.1 years; SD, 4.8). Overall, 42.8% were female, making up 55.9% and 38.2% of the COVID-19 and MIS-C groups, respectively. Overall, the frequencies of major complications at 6 months after initial presentation were: 16/195 (8.2%) cardiovascular, 11/154 (7.1%) pulmonary, 11/154 (7.1%) gastrointestinal/hepatic, 3/152 (2.0%) renal, and 3/189 (1.6%) neurologic. Organ system complications did not differ significantly between the COVID-19 and MIS-C groups. Six of 14 (42.9%) COVID-19 and 21/26 (80.7%) MIS-C participants with at least 1 six-month complication had no underlying medical condition that may have been associated with their complication(s). CONCLUSIONS Major complications were infrequent but observed in children without underlying medical conditions, underscoring the importance of prospective follow-up to optimize management and elucidate the complications associated with severe SARS-CoV-2 infection in children.
Subharmonic-aided pressure estimation for neoadjuvant chemotherapy response prediction in breast cancer
Choi, Sung In , Dogan, Basak, Wessner, Corinne E. , Porembka, Jessica, Machado, Priscilla , Ozcan, B. Bersu, Maysa, Abu-Khalaf, MD, MBA,, Hoyt, Kenneth , Dave, Jaydev, Giridhar, Karthik, Long, Zaiyang , Fazzio, Robert T. , Henrichsen, Tara, Forsberg, Flemming, Porembka, Jessica H. , Ozcan, B. Bersu , Unni, Nisha G , Abu‐Khalaf, Maysa , Dave, Jaydev , Henrichsen, Tara L. , Forsberg, Flemming , Nam, Kibo

Mayo Clinic

The Journal of the Acoustical Society of America | May 12, 2026 | Volume: 158 | Issue: 4_Supplement | Pages: A172-A173

10.1121/10.0040509 Get It

Elevated intratumoral interstitial fluid pressure (IFP) can negatively impact the efficacy of neoadjuvant chemotherapy (NAC) of breast cancer. This study aims to predict breast cancer pathological complete response (pCR) to NAC based on IFP measures by 3-D subharmonic-aided pressure estimation (SHAPE). SHAPE uses the inverse linear relationship between hydrostatic pressure and subharmonic signal magnitude from intravascular ultrasound contrast agents. Thirty-eight breast cancer patients undergoing NAC from three clinical sites were enrolled for this study. SHAPE data were collected for each subject at 0%, 10%, and 30% of NAC completion using a Logiq E9 system (GE HeathCare) equipped with an RSP6-16D probe. The contrast agent used was Definity (Lantheus Medical Imaging). The subharmonic signal gradients between tumor and adjacent normal tissue were calculated and compared with patient pathological response outcome using t-test and receiver operating characteristic (ROC) curve analysis. Pressure gradients between pCR (15 patients) and non-pCR (23 patients) groups were significantly different at 0 (p = 0.02), 10 (p = 0.03), and 30% (p = 0.0003) completion of NAC. Area under the curve values of 0.69, 0.77, and 0.86 were achieved at 0%, 10%, and 30% of NAC completion, respectively. Overall, SHAPE pressure gradients may aid prediction of NAC pathological response in breast cancer patients.
Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From JCO Global Oncology
Nguyễn, Long Thành , Hoyek, Celine , Magliano, Carlos, Mano, Max S., Prabhash, Kumar, Moraes, Fabio Ynoe , Loon, Katherine Van , Sonbol, Mohamad Bassam , Van Loon, Katherine , Kapoor, Akhil , Magliano, Carlos Alberto da Silva , Mano, Max S.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 11, 2026 | Volume: 46 | Issue: 3 | Pages: No page available

10.1200/edbk-26-528840 | PMID 42114030 Get It

By 2045, more than three quarters of global cancer deaths are projected to occur in low- and middle-income countries (LMICs); however, the global availability of cancer care remains constrained by high costs and inequitable access. Value-based frameworks that integrate clinical benefit with affordability, feasibility, and equity are essential to better guide research prioritization, resource allocation, and regulatory policies in LMICs. A key component of a value-based approach is the generation of high-quality, locally relevant data to support evidence-based implementation of cancer prevention and control strategies. Herein, we provide three contemporary examples from JCO Global Oncology which demonstrate how economic evaluation in cancer research can address locally relevant, health system–specific questions.
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
Investigators, The HCMR, Kolm, Paul, DiMarco, John P., Desai, M Y, Ho, Carolyn Y., Kwong, Raymond Y., Dolman, Sarahfaye , Nickens, Patrice Desvigne, GELLER, NANCY, Kim, Dong-Yun, Schulz-Menger, Jeanette, Friedrich, M G, Maron, Martin S., Appelbaum, Evan, Francis, Gary S., Greenberg, Barry, Jerosch-Herold, Michael, Piechnik, Stefan, Mahmod, Masliza, Jacoby, Daniel L., Baldassare, Lauren A., White, J, Helms, Adam S., Choudhury, Lubna , Michels, Michelle, Salerno, Michael , Heitner, Steven B., Masri, Ahmad, Prasad, Sanjay , Plein, S V E N, Madias, Christopher, Mahrholdt, Heiko , Bucciarelli-Ducci, C, Nightingale, Angus K. , Weinsaft, Jonathan W., McCann, Gerry P., Rossum, Albert van, Germans, Tjeerd , Williamson, Eric E. , Geske, Jeffrey B., Dawson, D, Mongeon, François‐Pierre , Olivotto, Iacopo, Crean, Andrew , Woo, Anna, Owens, Anjali T., Anderson, L , Biagini, Elena, Newby, David E., Andre, Florian, Berry, C, Kim, Bette, Larose, Eric, Abraham, Theodore P., Sherrid, Mark V., Gelfand, Eli V. , Nagueh, Sherif F. , Rimoldi, Ornella, Camici, Paolo, Elstein, Eleanor , Watkins, Hugh, Weintraub, William S., Neubauer, Stefan, Schulz‐Menger, Jeanette , Nightingale, Angus K , Dawson, Dana , Kramer, Christopher M. , Kolm, Paul , Desai, Milind Y. , Ho, Carolyn Y. , Kwong, Raymond Y.K. , Desvigne‐Nickens, Patrice , Kim, Dong-Yun, Friedrich, Matthias G. , Maron, Martin S. , Appelbaum, Evan A., Link, Mark S. , Greenberg, Barry, Jerosch‐Herold, Michael , Piechnik, Stefan Kazimierz , Mahmod, Masliza , Raman, Betty , Jacoby, Daniel Louis , Baldassarre, Lauren A. , White, James A. , Chiribiri, Amedeo , Helms, Adam S. , Michels, Michelle , Bradlow, William M. , Heitner, S B, Masri, Ahmad , Mohiddin, Saidi , Plein, Sven , Madias, Christopher A. , Bucciarelli‐Ducci, Chiara , Weinsaft, Jonathan W. , Kim, Han W. , McCann, Gerry P , Rossum, Albert C. van , Geske, Jeffrey B. , Flett, Andrew S. , Olivotto, Iacopo , Woo, Anna, Owens, Anjali , Sharma, Sanjay , Biagini, Elena , Newby, David E. , André, Florian , Berry, Colin , Larose, Éric , Abraham, Theodore P. , Hays, Allison G , Sherrid, Mark V. , Rimoldi, Ornella , Camici, Paolo G. , Autore, Camillo , Watkins, Hugh , Weintraub, William S. , Neubauer, Stefan

Mayo Clinic

JAMA | May 11, 2026 | Volume: 335 | Issue: 22 | Pages: 1959

10.1001/jama.2026.5633 | PMID 42113540 Get It

Importance Current risk prediction guidelines for hypertrophic cardiomyopathy predict only sudden cardiac death and are imperfect, leading to avoidable deaths and unnecessary implantable cardioverter defibrillators. Objective To combine prospectively collected clinical history, imaging, genetic, and biomarker data to improve risk prediction of adverse events in hypertrophic cardiomyopathy. Design, Setting, and Participants A total of 2750 patients with hypertrophic cardiomyopathy were prospectively enrolled in the registry-based study from 44 sites in North America and Europe with expertise in hypertrophic cardiomyopathy and cardiac magnetic resonance (CMR) imaging. Participants were enrolled from April 1, 2014, to April 7, 2017. Exposures Patients underwent a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced CMR. Patients were followed up yearly by telephone and through records review regarding event documentation. Main Outcomes and Measures The predefined composite adjudicated primary end point was time to first event for hypertrophic cardiomyopathy–related deaths; nonfatal sustained ventricular arrhythmias (VAs) requiring cardioversion or defibrillation; and left ventricular (LV) assist device implant or heart transplant. A secondary end point was a composite of sudden cardiac death and nonfatal VA events. The elastic-net method identified the most important predictors. Cox proportional hazards regression assessed associations with time to the first end point. Results Of the 2750 prospectively enrolled patients, 2698 (98%) had analyzable data after 9 were excluded because they had hypertrophic cardiomyopathy phenocopies and 43 withdrew. Of these remaining patients, 1919 (71%) were male, mean age was 50 years (SD, 11 years), and 423 (16%) were from underrepresented racial and minority groups. The mean follow-up was 6.9 years (SD, 2.1 years). The primary event model in 104 patients included LV scar as a percentage of LV mass by late gadolinium enhancement (LGE%; hazard ratio [HR], 1.86; 95% CI, 1.58-2.20; P &amp;lt; .001), LV mass index (HR, 1.09; 95% CI, 1.01-1.17; P = .03), LV end-systolic volume index (HR, 1.28; 95% CI, 1.12-1.46; P &amp;lt; .001 ), all per 10-unit increase, history of heart failure at study entry (HR, 2.89; 95% CI, 1.75-4.77; P &amp;lt; .001), and log N-terminal pro–B-type natriuretic peptide (NT-proBNP; HR, 1.41; 95% CI, 1.17-1.70; P &amp;lt; .001) level per log unit, (C index for all, 0.77). An LGE percentage of the LV mass of 9% or higher substantially increased the primary composite event rate ( P = .001). The secondary sudden cardiac death and VA risk factor model (in 69 patients) included LGE%, LV mass index, LV ejection fraction, and log(NT-proBNP) (C index, 0.76). Conclusions and Relevance These results provide prospective evidence for incorporating cardiac magnetic resonance and NT-proBNP in the evaluation of patients with hypertrophic cardiomyopathy. Trial Registration ClinicalTrials.gov Identifier: NCT01915615